Clinical trials: Advanced Breast Cancer Brain Metastasis
Brain Metastases, Generalized Malignancy, Primary
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in…
- Conditions
- Brain Metastases, Generalized Malignancy, Primary, Brain Lesions
- Trial name
- NCT02187822
- Testing
- TPI 287, Fractionated Stereotactic Radiotherapy (FSRT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Cancer, Malignant Neoplasm of Breast
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
There are 2 phases in this study: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenvatinib and Xeloda (capecitabine) that can…
- Conditions
- Advanced Cancer, Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage, Malignant Neoplasms of Digestive Organs
- Trial name
- NCT02915172
- Testing
- Lenvatinib, Capecitabine
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
This phase I/II trial studies the side effects and how well copanlisib works when given together with fulvestrant in treating patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT03803761
- Testing
- Copanlisib, Fulvestrant
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Metastatic, Breast Cancer Brain Metastases
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR-A1811 combined with pyrotinib in breast cancer with brain metastasis, and confirm the recommended phase 2 dose combined with preliminary results of…
- Trial name
- NCT06718933
- Testing
- SHR-A1811, Bevacizumab, Pyrotinib
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Cancer
Brain Metastasis in Breast Cancer Patients
The purpose of this epidemiologic study is to establish a population-based cohort of women with advanced stage breast cancer which can be used to quantify the frequency and timing of brain metastases, and other distant…
- Trial name
- NCT01077648
- Testing
- Trastuzumab or Lapatinib
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Metastatic Breast Cancer
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment…
- Trial name
- NCT06598046
- Testing
- Utidelone and capecitabine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Breast Cancer
Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
A study on the safety and efficacy of T-DXd in combination with local radiotherapy for brain metastases in HER2-Positive and HER2-Low breast cancer patients.
- Trial name
- NCT07117864
- Testing
- T-DXd concurrent brain radiotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- QIAO LI
Breast Cancer
Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy directed at the head is effective in preventing brain metastases in patients with advanced cancer.
- Trial name
- NCT00639366
- Testing
- trastuzumab, chemotherapy, radiation therapy
- Where
- 19 sites in United Kingdom
- Volunteers
- 390 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Trial name
- NCT07540572
- Testing
- IDE574, Fulvestrant injection
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Advanced Breast Cancer Brain Metastasis
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as a radiosensitizer in patients with advanced breast cancer brain metastasis.
- Trial name
- NCT06839547
- Testing
- Radiotherapy + Novel Anti-tumor Drug
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HER2-positive Advanced Breast Cancer, Brain Metastases
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined…
- Conditions
- HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT07100600
- Testing
- Trastuzumab Rezetecan, FSRT or WBRT
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital